127 related articles for article (PubMed ID: 986241)
21. Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells.
Rasey JS; Krohn KA; Grunbaum Z; Conroy PJ; Bauer K; Sutherland RM
Radiat Res; 1985 Apr; 102(1):76-85. PubMed ID: 3983371
[TBL] [Abstract][Full Text] [Related]
22. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors.
Cairns RA; Kalliomaki T; Hill RP
Cancer Res; 2001 Dec; 61(24):8903-8. PubMed ID: 11751415
[TBL] [Abstract][Full Text] [Related]
23. Testing of hypoxic cell radiosensitizers in vivo.
Rauth AM; Chin J; Marchow L; Paciga J
Br J Cancer Suppl; 1978 Jun; 3():202-5. PubMed ID: 277228
[TBL] [Abstract][Full Text] [Related]
24. Nitro reduction as an electronic switch for bioreductive drug activation.
Siim BG; Denny WA; Wilson WR
Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
[TBL] [Abstract][Full Text] [Related]
25. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
[TBL] [Abstract][Full Text] [Related]
26. Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography.
Akel G; Benard P; Canal P; Soula G
Cancer Chemother Pharmacol; 1986; 17(2):121-6. PubMed ID: 3719893
[TBL] [Abstract][Full Text] [Related]
27. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
[TBL] [Abstract][Full Text] [Related]
28. Radiation-induced reduction of nitroimidazole derivatives in aqueous solution.
Kagiya T; Ide H; Nishimoto S; Wada T
Int J Radiat Biol Relat Stud Phys Chem Med; 1983 Nov; 44(5):505-17. PubMed ID: 6605953
[TBL] [Abstract][Full Text] [Related]
29. Estimation of oxygen distribution in RIF-1 tumors by diffusion model-based interpretation of pimonidazole hypoxia and eppendorf measurements.
Pogue BW; Paulsen KD; O'Hara JA; Wilmot CM; Swartz HM
Radiat Res; 2001 Jan; 155(1 Pt 1):15-25. PubMed ID: 11121211
[TBL] [Abstract][Full Text] [Related]
30. Toxicity of diethylaminoreserpine to a transplantable tumor: the significance of the presence of hypoxic cells.
Lehnert S
Cancer Res; 1982 Aug; 42(8):3028-32. PubMed ID: 7093951
[TBL] [Abstract][Full Text] [Related]
31. Proceedings: Sensitization of hypoxic mammalian cells in vitro by some nitroimidazoles and nitropyrazoles.
Asquith JC; Watts M
Br J Radiol; 1975 Jan; 48(565):75. PubMed ID: 1109646
[No Abstract] [Full Text] [Related]
32. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
Busch TM; Hahn SM; Evans SM; Koch CJ
Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
[TBL] [Abstract][Full Text] [Related]
33. The potential for radiation sensitizers and possible strategy for use.
Whitmore GF
Laryngoscope; 1975 Jul; 85(7):1145-54. PubMed ID: 1097849
[TBL] [Abstract][Full Text] [Related]
34. Killing of EMT-6 cells by decays from isotopes incorporated on sensitizer adducts.
Roa WH; Chapman JD
Radiat Res; 1992 Nov; 132(2):248-53. PubMed ID: 1438707
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
36. Effects of dimethyl sulfoxide and hypoxic cell radiosensitizers on the radiation response of the KHT murine tumor in vivo.
Rauth AM; Paciga JE
Radiat Res; 1977 Feb; 69(2):248-57. PubMed ID: 841003
[No Abstract] [Full Text] [Related]
37. NLNQ-1, a 2-[3-(2-nitro-1-imidazolyl) propylamino]-3-chloro-1,4-naphthoquinone, as a hypoxia-selective cytotoxin and radiosensitizer.
Papadopoulou MV; Bloomer WD
In Vivo; 2008; 22(3):285-8. PubMed ID: 18610737
[TBL] [Abstract][Full Text] [Related]
38. Nitroimidazoles as anti-tumor agents.
Liu K; Zhu HL
Anticancer Agents Med Chem; 2011 Sep; 11(7):687-91. PubMed ID: 21521156
[TBL] [Abstract][Full Text] [Related]
39. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1.
Papadopoulou MV; Rosenzweig HS; Doddi M; Bloomer WD
Oncol Res; 1994; 6(9):439-48. PubMed ID: 7703530
[TBL] [Abstract][Full Text] [Related]
40. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia.
Olive PL; Durand RE; Raleigh JA; Luo C; Aquino-Parsons C
Br J Cancer; 2000 Dec; 83(11):1525-31. PubMed ID: 11076663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
